Form 4: Bio-Techne Corp: SVP General Counsel, Shane Bohnen, Reports Changes in Beneficial Ownership

Shane Bohnen, SVP General Counsel of Bio-Techne Corp, reports transactions involving common stock, stock options, and restricted stock units.

Summary

• On August 15, 2024, Shane Bohnen, SVP General Counsel of Bio-Techne Corp, filed a Form 4 with the SEC detailing changes in beneficial ownership.
• The transactions included the vesting of 49 restricted stock units, the acquisition of 10,012 performance restricted stock units, the acquisition of 5,006 restricted stock units, and the acquisition of 13,488 stock options.
• Bohnen also disposed of 15 shares of common stock to cover tax obligations at a price of $74.91.
• Following these transactions, Bohnen directly owns 1,681 shares of common stock.
• Bohnen also holds various stock options and restricted stock units with different vesting schedules and exercise prices.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine and reflect standard executive compensation practices. The acquisition of equity suggests confidence in the company's future performance.

Positives

• The acquisition of stock options and restricted stock units indicates a continued alignment of the executive's interests with those of the shareholders.
• The vesting of restricted stock units represents a form of compensation and incentive for the executive.

Negatives

• The disposal of 15 shares of common stock, while for tax obligations, slightly reduces the executive's direct holdings.

Risks

• Future performance goals tied to performance restricted stock units may not be achieved, impacting the actual value realized by the executive.
• Changes in the company's stock price could affect the value of the stock options and restricted stock units.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of stock options and restricted stock units suggest a long-term incentive structure for the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages including stock options and restricted stock units are standard practice among publicly traded companies, particularly in the biotech industry.
• Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and performance-based criteria are typical components designed to align executive performance with long-term shareholder value.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect standard executive compensation practices.
• Employees may be indirectly affected by the performance incentives tied to the executive's compensation.

Key Dates